Advisory Research’s Biote Corp. Warrant BTMDW Stock Holding History

Advisory Research’s Portfolio BTMDW Stock Details BTMDW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-128,292	Closed	-$53.9K	–	512
2023 Q1	$53.9K	Buy	128,292 +25,000	+24%	+$9.06K	0.01%	339
2022 Q4	$31K	Sell	103,292 -11,889	-10%	-$3.24K	﹤0.01%	352
2022 Q3	$39K	Buy	115,181 +21,178	+23%	+$6.87K	﹤0.01%	332
2022 Q2	$40K	Buy	94,003 +68,250	+265%	+$36.8K	﹤0.01%	327
2022 Q1	$14K	Buy	25,753 +750	+3%	+$356	﹤0.01%	391
2021 Q4	$18K	Sell	25,003 -519	-2%	-$418	﹤0.01%	343
2021 Q3	$20K	Hold	25,522	–	–	﹤0.01%	348
2021 Q2	$25K	Buy	+25,522	New	+$22.1K	﹤0.01%	345

Other funds holding BTMDW

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Advisory Research's BTMDW Position: Q2 2023 in Review

Advisory Research sold out of Biote Corp. Warrant (BTMDW) in Q2 2023, closing a stake of 128,292 shares — an estimated $53.9K sold.

Advisory Research first reported a position in BTMDW in Q2 2021 and held it in 8 quarters. The position peaked at $53.9K in Q1 2023. 2 funds tracked by Wall St. Rank hold BTMDW as of Q2 2023.

Advisory Research reported no remaining Biote Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Advisory Research sold 128,292 Biote Corp. Warrant shares in Q2 2023, an estimated $53.9K.
Advisory Research first reported a position in Biote Corp. Warrant in Q2 2021 and held it in 8 quarters.
Advisory Research's Biote Corp. Warrant position peaked at $53.9K in Q1 2023.
2 funds tracked by Wall St. Rank held Biote Corp. Warrant as of Q2 2023.

Based on Advisory Research's 13F filing for Q2 2023, filed 14 Aug 2023.